Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)
China · Delayed Price · Currency is CNY 16.53
-0.12 (-0.72%)
At close: Feb 6, 2026
SHA:600161 Revenue
Beijing Tiantan Biological Products had revenue of 1.35B CNY in the quarter ending September 30, 2025, with 9.96% growth. This brings the company's revenue in the last twelve months to 6.42B, up 22.78% year-over-year. In the year 2024, Beijing Tiantan Biological Products had annual revenue of 6.03B with 16.44% growth.
Revenue (ttm)
6.42B
Revenue Growth
+22.78%
P/S Ratio
5.09
Revenue / Employee
1.21M
Employees
5,298
Market Cap
32.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.03B | 851.42M | 16.44% |
| Dec 31, 2023 | 5.18B | 919.14M | 21.57% |
| Dec 31, 2022 | 4.26B | 149.15M | 3.63% |
| Dec 31, 2021 | 4.11B | 666.56M | 19.35% |
| Dec 31, 2020 | 3.45B | 163.74M | 4.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DaShenLin Pharmaceutical Group | 26.83B |
| Chongqing Zhifei Biological Products | 10.91B |
| Shanghai RAAS Blood Products | 7.95B |
| Asymchem Laboratories (Tianjin) | 6.29B |
| Shanghai Allist Pharmaceuticals | 4.76B |
| Yili Chuanning Biotechnology | 4.74B |
| Hualan Biological Engineering | 4.27B |
| Xiamen Amoytop Biotech | 3.34B |